We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genzyme's New Diagnostic Monitors Gleevec Resistance
Genzyme's New Diagnostic Monitors Gleevec Resistance
February 17, 2006
Biotech firm Genzyme has launched a diagnostic test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Novartis’ cancer drug Gleevec.